✦ LIBER ✦

P723 FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIES

✍ Scribed by Asselah, T.; Jensen, D.M.; Foster, G.R.; Sulkowski, M.S.; Ouzan, D.; Morano, L.; Buynak, R.; Agarwal, K.; Hassanein, T.; Forton, D.; Negro, F.; Genné, D.; Kaita, K.; Maieron, A.; Preotescu, L.; Sarrazin, C.; Zehnter, E.; Romero-Gómez, M.; Stern, J.O.; Quinson, A.-M.; Drulak, M.; Garcia, M.; Voss, F.; Böcher, W.; Ferenci, P.

Book ID: 122298142
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 84 KB
Volume: 60
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(14)60885-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Su1060 Faldaprevir Plus Pegylated Interf

Su1060 Faldaprevir Plus Pegylated Interferon/Ribavirin Did Not Increase Anaemia Compared With Pegylated Interferon/Ribavirin in HCV Genotype-1, Treatment-Naïve Patients: Pooled Analysis of Phase III Studies

✍ Asselah, Tarik; Jensen, Donald M.; Foster, Graham; Sulkowski, Mark; Ouzan, Denis 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 233 KB

P1129 EFFECT OF HCV GENOTYPE-1 SUBTYPE O

P1129 EFFECT OF HCV GENOTYPE-1 SUBTYPE ON RESPONSE TO FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: POOLED DATA FROM PHASE III TRIALS

✍ Jacobson, I.M.; Jensen, D.M.; Dieterich, D.; Sarrazin, C.; Foster, G.R.; Yoshida 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 67 KB

Su1056 Effect of HCV Genotype-1 Subtype

Su1056 Effect of HCV Genotype-1 Subtype on Response to Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin in Treatment-Naïve Patients: Pooled Data From Phase III Trials

✍ Jacobson, Ira M.; Jensen, Donald M.; Dieterich, Douglas T.; Sarrazin, Christoph; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 397 KB

P724 VIROLOGICAL RESPONSE IN TREATMENT-N

P724 VIROLOGICAL RESPONSE IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION RECEIVING FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IS UNAFFECTED BY RIBAVIRIN DOSE REDUCTION

✍ Asselah, T.; Jensen, D.M.; Foster, G.R.; Sulkowski, M.S.; Ouzan, D.; Morano, L.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Su1054 Ns3 Q80k Did Not Impact Efficacy

Su1054 Ns3 Q80k Did Not Impact Efficacy or Treatment-Emergent Resistance Patterns in HCV Genotype-1-Infected Patients Receiving Faldaprevir Plus Pegylated Interferon/Ribavirin in Three Phase III Trials

✍ Berger, Kristi; Sarrazin, Christoph; Ferenci, Peter; Jensen, Donald M.; Jacobson 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 396 KB

P1121 EARLY STOPPING RULES FOR FALDAPREV

P1121 EARLY STOPPING RULES FOR FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: EXPLORATORY STUDY OF POOLED DATA FROM PHASE III TRIALS

✍ Ferenci, P.; Dieterich, D.; Zeuzem, S.; Mantry, P.; Sarrazin, C.; Crespo, J.; Ta 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 83 KB